The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer

Fabio Gomes, Rebecca Tay, Jaseela Chiramel, Raffaele Califano

Research output: Contribution to journalArticlepeer-review

Abstract

Lung cancer is predominantly a disease of the elderly. This subgroup of patients poses many challenges and an appropriate geriatric assessment is crucial for treatment personalisation in order to reduce the risk of over- or under-treatment. Whilst cytotoxic chemotherapy has been the backbone of advanced non-small cell lung cancer (NSCLC) treatment for decades, the development of targeted agents for driver mutations such as EGFR, ALK, BRAF and ROS1 has changed the treatment paradigm and natural history of this disease. More recently, the development of immune checkpoint inhibitors has revolutionised treatment for a larger group of patients with locally advanced/metastatic disease. Limited data exist on safety and efficacy of these agents in the elderly population. Many questions remain regarding the available evidence for targeted therapies and immune checkpoint blockade in NSCLC and, in particular, their role in this subgroup of patients.
Original languageEnglish
Pages (from-to)819-834
JournalDrugs and Aging
Volume35
Issue number9
Early online date14 Aug 2018
DOIs
Publication statusPublished - 2018

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this